TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9061893

Group type: EXPERIMENTAL
Intervention: Negatively valenced TV news bulletin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral valenced TV news bulletin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Positively valenced TV news bulletin
Number of subjects: 0
Study: 7524629

Group type: EXPERIMENTAL
Intervention: Lugol's iodine staining technique
Number of subjects: 203
Study: 3282893

Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg b.i.d. (increased to 10 mg b.i.d. if needed)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 12.5 mg b.i.d. (increased to 25 mg b.i.d. if needed)
Number of subjects: 76
Study: 11341663

Group type: EXPERIMENTAL
Intervention: Coffee (280 ml)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 10
Study: 31356537

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg subcutaneously
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 29374995

Group type: EXPERIMENTAL
Intervention: Intraosseous injection (IO)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Inferior alveolar nerve block (IANB) with 3% mepivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Inferior alveolar nerve block (IANB)
Number of subjects: 60
Study: 26329802

Group type: EXPERIMENTAL
Intervention: Kinesio taping + exercise (n = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Exercise (n = 12)
Number of subjects: 24
Study: 25392248

Group type: EXPERIMENTAL
Intervention: Dual diagnosis enhanced programs
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: Dual diagnosis capable
Number of subjects: 261

Group type: COMPARATOR
Intervention: Addiction only services
Number of subjects: 261
Study: 22130359

Group type: EXPERIMENTAL
Intervention: Tubeless PCNL (group 1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard PCNL (group 2)
Number of subjects: 100
Study: 20665501

Group type: EXPERIMENTAL
Intervention: DCTER regimen (daunorubicin, cytarabine, thioguanine, etoposide, dexamethasone)
Number of subjects: 61

Group type: COMPARATOR
Intervention: IA combination (idarubicin and cytarabine)
Number of subjects: 61
Study: 17602073

Group type: EXPERIMENTAL
Intervention: Bevacizumab 5 mg/kg infused over 10 minutes
Number of subjects: 1077

Group type: COMPARATOR
Intervention: Bevacizumab 5 mg/kg infused over 30 minutes
Number of subjects: 1077

Group type: COMPARATOR
Intervention: Bevacizumab 5 mg/kg infused at a standard rate of 0.5 mg/kg/min
Number of subjects: 1077
Study: 16040284

Group type: EXPERIMENTAL
Intervention: Levofloxacin (300 mg b.d.)-based therapy with lansoprazole (30 mg b.d.) and amoxicillin (1000 mg b.d.) for 7 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Metronidazole (500 mg b.d.)-based therapy with lansoprazole (30 mg b.d.) and amoxicillin (1000 mg b.d.) for 7 days
Number of subjects: 60
Study: 12556743

Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolytic therapy using urokinase
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Catheter-directed thrombolytic therapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Anticoagulation with unfractionated or low molecular weight heparin followed by warfarin
Number of subjects: 63
Study: 10362203

Group type: EXPERIMENTAL
Intervention: Right Atrial Pacing (RAP)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Biatrial Pacing (BAP)
Number of subjects: 61

Group type: COMPARATOR
Intervention: No Atrial Pacing (NAP)
Number of subjects: 61
Study: 7795270

Group type: EXPERIMENTAL
Intervention: TMQ at 200 mg/m2 i.v. q 2 weeks
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: TMQ at 12 mg/m2 i.v. daily x 5
Number of subjects: 162

Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU) at 15 mg/kg i.v. weekly
Number of subjects: 162
Study: 2117680

Group type: EXPERIMENTAL
Intervention: Hypercapnia (PETCO2: 60mmHg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normocapnia (PETCO2: 40mmHg)
Number of subjects: 16
Study: 6971922

Group type: EXPERIMENTAL
Intervention: Vitamin D supplement of 400 IU/day
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30879881

Group type: EXPERIMENTAL
Intervention: Motivational SMS
Number of subjects: 4386

Group type: EXPERIMENTAL
Intervention: Self-regulatory SMS
Number of subjects: 4386

Group type: COMPARATOR
Intervention: No SMS (Control)
Number of subjects: 4386
Study: 29390477

Group type: EXPERIMENTAL
Intervention: Drotaverine hydrochloride (DHC) 80‐mg tablet, 3 times daily for 4 weeks
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo 80‐mg tablet, 3 times daily for 4 weeks
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Drotaverine hydrochloride (DHC)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 26021211

Group type: EXPERIMENTAL
Intervention: Electrocautery incision
Number of subjects: 82

Group type: COMPARATOR
Intervention: Scalpel incision
Number of subjects: 82
Study: 24875433

Group type: EXPERIMENTAL
Intervention: Immediate intervention
Number of subjects: 142

Group type: COMPARATOR
Intervention: Delayed intervention
Number of subjects: 142
Study: 22000773

Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine (120 μg for the right coronary artery and 180 μg for the left coronary artery)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Intracoronary adenosine
Number of subjects: 260
Study: 19685728

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) of Ashi-point, Jiaji (EX‐B 2), Zhigou (SJ 6) and Houxi (SI 3), once daily for 10 times
Number of subjects: 80

Group type: COMPARATOR
Intervention: Medication group (valaciclovir hydrochloride 300 mg/time, b.i.d. and vitamin B1 10 mg/time, t.i.d., for 10 days)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) group
Number of subjects: 80
Study: 18161262

Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg/day
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 15640898

Group type: EXPERIMENTAL
Intervention: Solanum melongena (SM) 450 mg twice daily
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo 450 mg twice daily
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Solanum melongena (SM)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 11584350

Group type: EXPERIMENTAL
Intervention: Telephone nursing intervention weekly for 3 months
Number of subjects: 15

Group type: COMPARATOR
Intervention: Informational calls at weeks 6 and 12
Number of subjects: 15
Study: 10099041

Group type: EXPERIMENTAL
Intervention: Tiagabine (titrated from 8 to 24 mg/d)
Number of subjects: 12
Study: 8136389

Group type: EXPERIMENTAL
Intervention: Hypodense solution of mannitol (n = 23)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Suspension of BaSO4 (n = 14)
Number of subjects: 37
Study: 2491962

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (hexamethylmelamine, 5‐fluorouracil, cisplatin, and prednimustine)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Prednimustine alone
Number of subjects: 76
Study: 1091994

Group type: EXPERIMENTAL
Intervention: Fenoprofen calcium
Number of subjects: 45
Study: 31020550

Group type: EXPERIMENTAL
Intervention: Hypertension (HT) prevalence measurement
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Isolated systolic hypertension (ISH) prevalence measurement
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Risk factors analysis for HT
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Risk factors analysis for ISH
Number of subjects: 354
Study: 27868341

Group type: EXPERIMENTAL
Intervention: Acellular synthetic matrix plus standard care (ASM + SC)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard care alone (SC)
Number of subjects: 53
Study: 25963675

Group type: EXPERIMENTAL
Intervention: SALT (Supraglottic Airway Laryngopharyngeal Tube)
Number of subjects: 210

Group type: COMPARATOR
Intervention: ILMA
Number of subjects: 210

Group type: COMPARATOR
Intervention: Cobra PLA
Number of subjects: 210

Group type: COMPARATOR
Intervention: Air‐Q
Number of subjects: 210
Study: 23451885

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE) 120 mg twice daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 21766075

Group type: EXPERIMENTAL
Intervention: Candida species in RT cultures
Number of subjects: 274

Group type: COMPARATOR
Intervention: No Candida species in RT cultures
Number of subjects: 274
Study: 18854724

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER < or =225 mg/day
Number of subjects: 1096

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1096
Study: 16614416

Group type: EXPERIMENTAL
Intervention: CAF in capsule form (4.45 mg/kg body weight)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: RCOF (4.45 mg/kg body weight caffeine)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: DECAF (equal in volume to the RCOF trial)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Dextrose (placebo, PL)
Number of subjects: 11
Study: 16450533

Group type: EXPERIMENTAL
Intervention: Single dose of oral azithromycin (20 mg/kg)
Number of subjects: 772

Group type: COMPARATOR
Intervention: Matched controls without trachoma
Number of subjects: 772
Study: 10720508

Group type: EXPERIMENTAL
Intervention: rgp160
Number of subjects: 608

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 608
Study: 9265807

Group type: EXPERIMENTAL
Intervention: Experimental group received two 50-minute sessions embedding suggestions from Gurdjieff.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group read material on achieving increased control.
Number of subjects: 24
Study: 7688381

Group type: EXPERIMENTAL
Intervention: RU 486 (200 mg orally) 12 hours before surgical interruption
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: RU 486 (200 mg orally) 24 hours before surgical interruption
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (control group) 24 hours before vacuum aspiration
Number of subjects: 60
Study: 3091164

Group type: EXPERIMENTAL
Intervention: Captopril (25‐50 mg twice a day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Captopril (12 weeks treatment)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31790073

Group type: EXPERIMENTAL
Intervention: Casino shifts (2000 to 0400 hours and 0400 to 1200 hours)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Standard overnight shifts (midnight to 0800 hours)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Mood faces rating scale
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 10-item postblock survey based on WHO domains for quality of life
Number of subjects: 124
Study: 28887843

Group type: EXPERIMENTAL
Intervention: Virgin Olive Oil (VOO) ingestion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes in HDL-related variables after VOO ingestion
Number of subjects: 0
Study: 26266427

Group type: EXPERIMENTAL
Intervention: Olopatadine 0.77%
Number of subjects: 345

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 345
Study: 24646101

Group type: EXPERIMENTAL
Intervention: GnRH analog injections plus daily topical testosterone gel
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 22568998

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interferon-α (IFN-α)
Number of subjects: 0
Study: 18636265

Group type: EXPERIMENTAL
Intervention: Single intravitreal injection of 1.25 mg bevacizumab
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Second injection of bevacizumab after a mean of 19+/‐8 weeks
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Second injection of bevacizumab
Number of subjects: 32
Study: 17336650

Group type: EXPERIMENTAL
Intervention: Mild treatment (mild ovarian stimulation with GnRH antagonist co-treatment and single embryo transfer)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Standard treatment (stimulation with GnRH agonist long-protocol and transfer of two embryos)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Mild treatment
Number of subjects: 404

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 404
Study: 12691137

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation (ABMT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tyrosine-kinase inhibitor STI 571
Number of subjects: 0
Study: 10819855

Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 531

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 531
Study: 8623127

Group type: EXPERIMENTAL
Intervention: UVB-irradiated platelet concentrates (PCs)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control, nonirradiated platelet concentrates (PCs)
Number of subjects: 50
Study: 1616322

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 10-deazaaminopterin
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control
Number of subjects: 26
Study: 6696358

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutrophil zinc levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zinc levels in plasma or erythrocytes
Number of subjects: 0
Study: 3516096

Group type: EXPERIMENTAL
Intervention: Tolazamide (sulfonylurea)
Number of subjects: 11
Study: 29164312

Group type: EXPERIMENTAL
Intervention: Rotigotine in combination with levodopa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rotigotine
Number of subjects: 0
Study: 27459163

Group type: EXPERIMENTAL
Intervention: Incentive group (voucher for testing)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Education group (control)
Number of subjects: 202
Study: 25290792

Group type: EXPERIMENTAL
Intervention: Primary DES
Number of subjects: 27

Group type: COMPARATOR
Intervention: PTA
Number of subjects: 27
Study: 23035006

Group type: EXPERIMENTAL
Intervention: Interferential current electro-massage
Number of subjects: 62

Group type: COMPARATOR
Intervention: Superficial lower back massage
Number of subjects: 62
Study: 20368905

Group type: EXPERIMENTAL
Intervention: Iloperidone (12 to 24 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Iloperidone
Number of subjects: 0
Study: 19109853

Group type: EXPERIMENTAL
Intervention: Interactive computerized modules
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (existing material)
Number of subjects: 102
Study: 16633107

Group type: EXPERIMENTAL
Intervention: Octreotide (300 microg twice per day) with diuretics (furosemide and spironolactone)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Octreotide (300 microg twice per day) alone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diuretics (furosemide and spironolactone) alone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diuretics (furosemide and spironolactone) discontinued for 7 days
Number of subjects: 20
Study: 14530477

Group type: EXPERIMENTAL
Intervention: Fuzzy logic-based automatic quantitative analysis software for myocardial SPECT
Number of subjects: 343
Study: 10902750

Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 15

Group type: COMPARATOR
Intervention: Healthy control subjects with A77 1726
Number of subjects: 15
Study: 8936710

Group type: EXPERIMENTAL
Intervention: Hypnotically-induced vasodilation (hypnosis with biofeedback and autogenics)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 30
Study: 1405984

Group type: EXPERIMENTAL
Intervention: Sucralfate, given four times daily for 10 days as a swish and swallow
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 34
Study: 4078027

Group type: EXPERIMENTAL
Intervention: Intravenous indoprofen 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous indoprofen 400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular pentazocine 15 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular pentazocine 30 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall evaluation of pain relief
Number of subjects: 0
Study: 29368116

Group type: EXPERIMENTAL
Intervention: Telephonic Barthel Index (BI) assessment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Face-to-face assessment of Barthel Index (BI)
Number of subjects: 120
Study: 26568636

Group type: EXPERIMENTAL
Intervention: Spectral-domain optical coherence tomography (SD-OCT) measurements
Number of subjects: 29
Study: 23866920

Group type: EXPERIMENTAL
Intervention: ACT plus usual care
Number of subjects: 73

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 73
Study: 22951521

Group type: EXPERIMENTAL
Intervention: Angiotensin receptor blocker (ARB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-dihydropyridine calcium channel blocker (CCB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both ARB and CCB
Number of subjects: 60
Study: 20149946

Group type: EXPERIMENTAL
Intervention: Traditional instruction
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Case-based instruction
Number of subjects: 90

Group type: COMPARATOR
Intervention: Web-based instruction
Number of subjects: 90
Study: 18677237

Group type: EXPERIMENTAL
Intervention: Cellumed (high viscosity)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Refresh Contacts (low viscosity)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Chronic protection (1 week prophylactic use of the solution)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Unprotected (no test solution used)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Immediate protection (test solution instilled just before application of TST)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Relief (test solution instilled just after application of TST)
Number of subjects: 12
Study: 15671558

Group type: EXPERIMENTAL
Intervention: IL-2 plus HDC
Number of subjects: 19

Group type: COMPARATOR
Intervention: IL-2 alone
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: HDC + IL-2
Number of subjects: 19
Study: 12731666

Group type: EXPERIMENTAL
Intervention: Eradication of Helicobacter pylori in 29 infected ITP patients (93% success rate, 27 patients)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Eradication of Helicobacter pylori in 29 infected ITP patients
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Patients who achieved a major response
Number of subjects: 61
Study: 10390264

Group type: EXPERIMENTAL
Intervention: Oral cefixime for 14 days (double dose on day 1)
Number of subjects: 306

Group type: COMPARATOR
Intervention: Initial intravenous cefotaxime for 3 days followed by oral cefixime for 11 days
Number of subjects: 306
Study: 8814691

Group type: EXPERIMENTAL
Intervention: Oral pamidronate, 300 mg/day (n = 65)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (n = 59)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Quality-of-life measurements
Number of subjects: 124
Study: 2004793

Group type: EXPERIMENTAL
Intervention: Intravenous metoclopramide (20 mg)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (2 ml dextrose)
Number of subjects: 49
Study: 6366125

Group type: EXPERIMENTAL
Intervention: CMF 12 cycles
Number of subjects: 0

Group type: COMPARATOR
Intervention: CMF 6 cycles
Number of subjects: 0
Study: 31233996

Group type: EXPERIMENTAL
Intervention: Event Recorder Feedback group
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combined intervention group (Event Recorder Feedback and parent communication)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study: 28065624

Group type: EXPERIMENTAL
Intervention: Unicondylar knee arthroplasty (UKA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 80
Study: 26190091

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (1440El.U; Havrix; GSK Vaccines) administered according to a 0-6 month schedule.
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (1440El.U; Havrix; GSK Vaccines) administered according to a 0-12 month schedule.
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: HAV booster administration (1440El.U) after loss of circulating anti-HAV antibodies.
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Mathematical modelling for long-term persistence predictions.
Number of subjects: 121
Study: 23422357

Group type: EXPERIMENTAL
Intervention: Caffeine intake (high quintile >371 mg/day)
Number of subjects: 2475

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee consumption
Number of subjects: 2475

Group type: EXPERIMENTAL
Intervention: Caffeine intake (interaction with vitamin B supplementation)
Number of subjects: 2475
Study: 21703023

Group type: EXPERIMENTAL
Intervention: Clinician reminders to reconsider aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinician and patient messages to reconsider aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Academic detailing (all practices)
Number of subjects: 0
Study: 19335932

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT) plus Treatment as Usual (TAU)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) alone
Number of subjects: 77
Study: 19681253

Group type: EXPERIMENTAL
Intervention: 6.5% hydrogen peroxide whitening strips
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo strips
Number of subjects: 30
Study: 15498043

Group type: EXPERIMENTAL
Intervention: Daily supplement of vitamins (50 mg/day of vitamin E and 250 mg/day of vitamin C)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 11280825

Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy (FLEC protocol), median of 3.5 cycles
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Intra-arterial chemotherapy (FLEC protocol)
Number of subjects: 135